[Management of phenylketonuria and hyperphenylalaninemia: the French guidelines]

V Abadie1, J Berthelot, F Feillet

  • 1Fédération de pédiatrie, hôpital Necker-Enfants-Malades, assistance publique-hôpitaux de Paris, 149, rue de Sèvres, 75015 Paris, France. veronique.abadie@nck.ap-hop-paris.fr

Insights

Phenylketonuria (PKU), an inherited metabolic disorder, requires early low-phenylalanine diet intervention. Lifelong monitoring is crucial for managing PKU and preventing maternal PKU complications.

Area of Science:

  • Metabolic disorders
  • Genetics
  • Public health

Context:

  • Phenylketonuria (PKU) affects 1 in 15,000 births.
  • France implemented national neonatal screening for PKU in 1978.
  • Established national guidelines ensure optimal patient diagnosis and treatment.

Purpose:

  • To outline the established French guidelines for PKU diagnosis and management.
  • To detail the dietary interventions and monitoring protocols for PKU patients.
  • To emphasize the importance of lifelong follow-up for PKU management and maternal PKU prevention.

Summary:

  • PKU management involves a low-phenylalanine diet initiated in the neonatal period.
  • Plasma phenylalanine levels should be maintained between 2-5 mg/dl until age 10.
  • Dietary relaxation is permitted post-adolescence with continued monitoring, and lifelong follow-up is essential.

Impact:

  • Early and consistent PKU management improves patient outcomes.
  • Adherence to guidelines ensures standardized care across regional centers.
  • Lifelong monitoring prevents complications associated with PKU and maternal PKU.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...